Transition from Community-based Integrated Care System to Community-based Symbiosis Society

2017 ◽  
Vol 26 (2) ◽  
pp. 71-88
Author(s):  
Eun-Hwan Oh ◽  
Keyword(s):  
Integrated Care ◽  
Community Based ◽  
Care System

Geography over doctrine? Factors affecting the role of Buddhist priests in a community‐based integrated care system

2021 ◽  
Author(s):  
Yukan Ogawa ◽  
Akinori Takase ◽  
Masaya Shimmei ◽  
Chiaki Ura ◽  
Machiko Nakagawa ◽  
...  
Keyword(s):  
Integrated Care ◽  
Community Based ◽  
Factors Affecting ◽  
Care System

Development of the dementia assessment sheet for community-based integrated care system

2016 ◽  
Vol 16 ◽  
pp. 123-131 ◽  
Author(s):  
Shuichi Awata ◽  
Mika Sugiyama ◽  
Kae Ito ◽  
Chiaki Ura ◽  
Fumiko Miyamae ◽  
...  
Keyword(s):  
Integrated Care ◽  
Community Based ◽  
Assessment Sheet ◽  
Care System

scholarly journals Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism

2021 ◽  
Vol 16 (4) ◽  
pp. 599-612
Author(s):  
Tetsuo Shoji ◽  
Shinya Nakatani ◽  
Daijiro Kabata ◽  
Katsuhito Mori ◽  
Ayumi Shintani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Secondary Hyperparathyroidism ◽  
Integrated Care ◽  
Vitamin D Receptor ◽  
Handgrip Strength ◽  
Interquartile Range ◽  
Community Based ◽  
Link Type ◽  
Assessment Sheet ◽  
Care System

Background and objectivesVitamin D receptor activators and calcimimetics (calcium-sensing receptor agonists) are two major options for medical treatment of secondary hyperparathyroidism. A higher serum calcification propensity (a shorter T50 value) is a novel surrogate marker of calcification stress and mortality in patients with CKD. We tested a hypothesis that a calcimimetic agent etelcalcetide is more effective in increasing T50 value than a vitamin D receptor activator maxacalcitol.Design, setting, participants, & measurementsA randomized, multicenter, open-label, blinded end point trial with active control was conducted in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. Patients were randomly assigned to receive intravenous etelcalcetide 5 mg thrice weekly (etelcalcetide group) or intravenous maxacalcitol 5 or 10 µg thrice weekly (maxacalcitol group). The primary, secondary, and tertiary outcomes were changes in T50 value, handgrip strength, and score of the Dementia Assessment Sheet for Community-Based Integrated Care System from baseline to 12 months, respectively.ResultsIn total, 425 patients from 23 dialysis centers were screened for eligibility, 326 patients were randomized (etelcalcetide, n=167; control, n=159), and 321 were included in the intention-to-treat analysis (median age, 66 years; 113 women [35%]). The median (interquartile range) of T50 value was changed from 116 minutes (interquartile range, 90–151) to 131 minutes (interquartile range, 102–176) in the maxacalcitol group, whereas it was changed from 123 minutes (interquartile range, 98–174) to 166 minutes (interquartile range, 127–218) in the etelcalcetide group. The increase in T50 value was significantly greater in the etelcalcetide group (difference in change, 20 minutes; 95% confidence interval, 7 to 34 minutes; P=0.004). No significant between-group difference was found in the change in handgrip strength or in the Dementia Assessment Sheet for Community-Based Integrated Care System score.ConclusionsEtelcalcetide was more effective in increasing T50 value than maxacalcitol among patients on hemodialysis with secondary hyperparathyroidism. There was no difference in handgrip strength or cognition between the two drugs.Clinical Trial registry name and registration number:VICTORY; UMIN000030636 and jRCTs051180156

Sign in / Sign up

Export Citation Format

Share Document